Bausch & Lomb v. Slayback Pharma: Brimonidine Patent Case Consolidated in 8 Days
Bausch & Lomb, Bausch & Lomb Ireland Limited, and Eye Therapies, LLC filed suit against Slayback Pharma and Dr. Reddy's Laboratories in New Jersey District Court over US11833245B2, covering Brimonidine Tartrate Ophthalmic Solution 0.025%. Within 8 days, the court ordered consolidation into the existing lead case, Civil Action No. 21-16766.
Pharma patent consolidation: Brimonidine Tartrate dispute merged into lead case
On December 5, 2023, Bausch & Lomb, Inc., Bausch & Lomb Ireland Limited, and Eye Therapies, LLC filed an infringement action in the U.S. District Court for the District of New Jersey against Slayback Pharma LLC, Slayback Pharma India LLP, Dr. Reddy's Laboratories SA, and Dr. Reddy's Laboratories, Inc. The suit asserted US11833245B2, a patent covering Brimonidine Tartrate Ophthalmic Solution 0.025%, a topical ophthalmic product used for the temporary relief of redness of the eye.
The recorded basis of termination is 'Case Consolidated.' The docket order stipulated that Civil Action No. 21-16766 shall serve as the lead case, directed the Clerk to close Civil Action No. 23-22906, and extended the defendants' deadline to respond to the complaint alleging infringement of the '245 patent to January 19, 2024. All future filings were directed to the lead case docket only.
The consolidation occurred just 8 days after filing, suggesting this action was filed as a companion or related case to already-pending litigation against the same or overlapping defendants. The substantive merits of the infringement claims remain to be litigated within Civil Action No. 21-16766. The specific terms of any underlying agreements between the parties are not disclosed in the available record for this docket.
See Complete Case & Patent Analysis →Filing to Case Consolidated in 8 days
From filing to consolidation order — one of the shortest docket lifecycles in ANDA-related pharma litigation
US11833245B2 — Brimonidine Tartrate Ophthalmic Solution 0.025%
Any pharmaceutical company, generic manufacturer, or contract development organisation working on Brimonidine Tartrate ophthalmic formulations — particularly at or near 0.025% concentration — faces active enforcement risk from US11833245B2. With multiple defendants already named and consolidated into ongoing litigation in New Jersey, the patent holders have demonstrated willingness to pursue parallel infringement actions. An FTO analysis is warranted before advancing an ANDA filing or product launch in this category.
Official order — verbatim text
The court's stipulation and order consolidated this newly filed case into the existing lead docket, Civil Action No. 21-16766, within 8 days of filing. The order directs closure of this docket and grants defendants an extended answer deadline, but makes no merits determination on infringement of US11833245B2. The substantive dispute over Brimonidine Tartrate Ophthalmic Solution 0.025% continues in the lead case.
What case consolidation means for this docket
Consolidation under Federal Rule of Civil Procedure 42(a) allows a court to combine cases sharing common questions of law or fact. Here, the New Jersey District Court ordered this action merged into the existing lead case, Civil Action No. 21-16766. This docket is administratively closed; all substantive proceedings, filings, and rulings now occur exclusively in the lead case.
Merged into 21-16766Same court, single docket — no venue change
Unlike a transfer under 28 U.S.C. § 1404, consolidation here kept the case within the District of New Jersey. The parties, claims, and patent at issue remain the same; only the docket number changes. Practitioners should monitor Civil Action No. 21-16766 for all scheduling orders, claim construction proceedings, and merits rulings going forward.
District of New Jersey retainedResponse deadline extended to January 19, 2024
As part of the consolidation order, defendants' deadline to respond to the complaint alleging infringement of the '245 patent was extended to January 19, 2024. This extension is consistent with standard practice when cases are consolidated close to filing, providing defendants adequate time to respond within the unified lead-case framework rather than on the compressed original schedule.
Answer deadline: Jan 19, 2024Merits to be decided in the lead case proceeding
With this docket closed, all infringement claims regarding US11833245B2 and Brimonidine Tartrate Ophthalmic Solution 0.025% will be adjudicated in Civil Action No. 21-16766. Stakeholders — including competing generic manufacturers and patent challengers — should track that lead case for claim construction, summary judgment, and trial scheduling relevant to this ophthalmic formulation patent.
Track Civil Action 21-16766Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bausch & Lomb, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Bausch & Lomb Ireland Limited | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Eye Therapies, LLC | Company | Search in Eureka ↗ |
| Defendant | Slayback Pharma, LLC | Company | /Search in Eureka ↗ |
| Co-Defendant | Dr. Reddys Laboratories, SA | Company | Search in Eureka ↗ |
| Co-Defendant | Dr. Reddy's Laboratories, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Slayback Pharma India, LLP | Company | Search in Eureka ↗ |
| Plaintiff counsel | Bryan C. Diner | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Justin James Hasford | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | Law Firm | Representing Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Bausch & Lomb, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the ophthalmic formulation patent space
Forward-looking patent and R&D intelligence derived from Bausch & Lomb's enforcement of US11833245B2 across the Brimonidine Tartrate and ophthalmic drug delivery landscape.
Bausch & Lomb's ophthalmic formulation patent activity
Bausch & Lomb's decision to enforce US11833245B2 alongside co-plaintiff Eye Therapies, LLC suggests a layered patent portfolio strategy around Brimonidine Tartrate ophthalmic products. Monitoring their broader filing activity in alpha-2 adrenergic agonist formulations and ophthalmic delivery systems may reveal additional IP barriers relevant to generic and branded competitors in this category.
Bausch & Lomb IP portfolioFiling trends in Brimonidine Tartrate ophthalmic formulations
The ophthalmic redness-relief segment is an active IP filing area, with innovators and generics competing on formulation parameters such as concentration, preservative systems, and excipient profiles. Tracking patent filings around Brimonidine Tartrate 0.025% and closely related ophthalmic alpha agonist formulations can surface white-space opportunities or emerging barriers ahead of regulatory filings.
Brimonidine ophthalmic filing trendsSlayback Pharma and Dr. Reddy's ophthalmic patent positions
As defendants in this consolidated ANDA action, Slayback Pharma and Dr. Reddy's Laboratories are active players in the generic ophthalmic pharmaceutical space. Analysing their own patent filings, ANDA paragraph IV certifications, and R&D pipelines in ophthalmic formulations can reveal competitive positioning and potential design-around strategies in the Brimonidine category.
Generic ophthalmic IP landscapeAdjacent ophthalmic redness-relief formulation opportunities
The enforcement perimeter around Brimonidine Tartrate 0.025% may create white-space opportunities in alternative concentrations, novel excipient combinations, or differentiated delivery mechanisms for ophthalmic redness relief. Mapping the claim boundaries of US11833245B2 against adjacent formulation space can help R&D teams identify patentable differentiation pathways that avoid the existing IP perimeter.
Ophthalmic formulation white spaceSimilar ophthalmic drug patent cases in New Jersey District Court
Explore related ANDA infringement actions involving ophthalmic formulation patents litigated in the District of New Jersey, including other Brimonidine Tartrate and alpha-2 agonist cases.
What this case signals for the ophthalmic pharma IP landscape
A consolidation after 8 days signals coordinated, multi-defendant enforcement of the Brimonidine Tartrate '245 patent by Bausch & Lomb.
Multi-defendant enforcement strategy signals broad patent perimeter defence
Filing against both Slayback Pharma and Dr. Reddy's Laboratories simultaneously — then consolidating — is consistent with a coordinated ANDA litigation strategy. Companies in the generic ophthalmic space should monitor both defendants' ANDA filings and the lead case docket for claim scope developments that could affect their own market-entry timelines.
US11833245B2 remains actively enforced — FTO exposure is real
The consolidation does not resolve the infringement claims; it centralises them. Any generic manufacturer developing or seeking approval for a Brimonidine Tartrate ophthalmic formulation at 0.025% concentration should treat this patent as an active enforcement risk and conduct a current freedom-to-operate analysis against the '245 patent claims.
Bausch v Slayback — key questions answered
This is a patent infringement action filed by Bausch & Lomb, Inc., Bausch & Lomb Ireland Limited, and Eye Therapies, LLC against Slayback Pharma LLC, Slayback Pharma India LLP, Dr. Reddy's Laboratories SA, and Dr. Reddy's Laboratories, Inc. in the District of New Jersey, asserting US11833245B2, which covers Brimonidine Tartrate Ophthalmic Solution 0.025%. The case was consolidated into lead case Civil Action No. 21-16766 within 8 days of filing.
The case was closed because the court ordered it consolidated into Civil Action No. 21-16766, designated as the lead case. The stipulation and order directed the Clerk to close this docket and required all future filings to be made in the lead case only. No merits ruling was issued; the closure reflects administrative consolidation, not a substantive resolution of the infringement claims.
The patent at issue is US11833245B2, filed under application number US18/103404. It covers Brimonidine Tartrate Ophthalmic Solution at 0.025% concentration, an alpha-2 adrenergic agonist formulated for topical ocular use. The patent is held by or licensed to Bausch & Lomb and Eye Therapies, LLC, who jointly enforced it in this action.
A 'Case Consolidated' termination means the court merged this action into another related case — here, Civil Action No. 21-16766 — under Federal Rule of Civil Procedure 42(a). The docket is administratively closed, but the underlying infringement claims are not dismissed or resolved. All substantive proceedings continue in the lead case. It is not a merits disposition and does not constitute a win or loss for either party.
Following consolidation, all proceedings regarding US11833245B2 and the Brimonidine Tartrate Ophthalmic Solution 0.025% infringement claims are being conducted in Civil Action No. 21-16766 in the U.S. District Court for the District of New Jersey. Defendants were given until January 19, 2024 to respond to the complaint in that lead case.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.